nav arrow

About Joel S. Ross, MD

In 1981 I was placed in charge of the care of my first patient with dementia. She was an elderly woman who was unable to talk, nor walk nor communicate in any manner.

Both saddened and stunned by the lack of awareness to her surroundings, I searched her medical record. I found the diagnosis of "senility, end stage". This did not tell me why she had become so ill and there was not textbook talking about "senility" as a disease. I decided my career would follow a path into geriatrics. Fortunately I was offered a fellowship at the prestigious Mt. Sinai Med School Geriatrics Dept under the first National Institutes of Aging Director, Dr. Robert N. Butler. He and his team taught me about Alzheimer's Disease. I spent two years studying this newly described condition and worked with some of the world's leading authorities. Over the next 31 years I sought what is the cause of the disease and why it affects some but not others at ages as early as 45 or as old as 105.

The prevailing theories over the past few decades have focused on "bad amyloid" and "bad Tau". I have found that the amyloid and tau the major pharmaceutical companies are seeking to remove from the brains of AD patients might not be toxic at all. They might be a healthy/physiological response to a true toxic protein: acetylated Tau (Ac-Tau) for short. In a now landmark article by Min et al published Sept 21, 2015 in Nature Medicine, their Gladstone Institute found that by using salsalate (an available by prescription anti-inflammatory drug), they can effectively stop progression of AD in the mouse model of ac-Tau. Studies using salsalate are being planned in AD patients at the Univ of California, San Francisco.

I recognized that the current formulation of salsalate is very short acting and unlikely to work in AD patients as it did for the mouse model of AD. I have tested salsalate in many AD patients in my practice with no benefit.

I founded CogWellin to establish a new pharmaceutical company that will produce a long acting once a day salsalate to hopefully once and for all rid the world of AD.

It will tested for both prevention of AD as well as to stop AD in it's tracks.

CogWellin is also actively developing a new diagnostic test (called a "biomarker") that might be the best test to confirm presence or absence of AD in those with or even without symptoms.

dr joel s ross md